Legal & General Group
ONCT

Legal & General Group’s Oncternal Therapeutics, Inc. Common Stock ONCT Stock Holding History

Legal & General Group’s Portfolio ONCT Stock Details ONCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-177
Closed -$4K – 3508
2022
Q2 		$4K Hold
177
– – ﹤0.01% 3466
2022
Q1 		$5K Hold
177
– – ﹤0.01% 3514
2021
Q4 		$8K Hold
177
– – ﹤0.01% 3509
2021
Q3 		$15K Hold
177
– – ﹤0.01% 3367
2021
Q2 		$17K Buy
+177
New +$21K ﹤0.01% 3354
2019
Q3 		– Sell
-5
Closed -$1K – 3433
2019
Q2 		$1K Hold
5
– – ﹤0.01% 3489
2019
Q1 		$1K Hold
5
– – ﹤0.01% 3345
2018
Q4 		$1K Hold
5
– – ﹤0.01% 3379
2018
Q3 		$1K Hold
5
– – ﹤0.01% 3386
2018
Q2 		$10K Buy
+5
New +$12.7K ﹤0.01% 3304

Other funds holding ONCT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
QPW
Quantum Private Wealth Tampa, Florida $390M AUM 58.18% 1-Year Est. Return
BC
BIT Capital Berlin, Germany $2.07B AUM 157.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
BJL
Brighton Jones LLC Seattle, Washington $2.37B AUM 16.36% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Legal & General Group's ONCT Position: Q3 2022 in Review

Legal & General Group sold out of Oncternal Therapeutics, Inc. Common Stock (ONCT) in Q3 2022, closing a stake of 177 shares — an estimated $4K sold.

Legal & General Group first reported a position in ONCT in Q2 2018 and held it in 10 quarters. The position peaked at $17K in Q2 2021. 61 funds tracked by Wall St. Rank hold ONCT as of Q3 2022.

  • Legal & General Group reported no remaining Oncternal Therapeutics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • Legal & General Group sold 177 Oncternal Therapeutics, Inc. Common Stock shares in Q3 2022, an estimated $4K.
  • Legal & General Group first reported a position in Oncternal Therapeutics, Inc. Common Stock in Q2 2018 and held it in 10 quarters.
  • Legal & General Group's Oncternal Therapeutics, Inc. Common Stock position peaked at $17K in Q2 2021.
  • 61 funds tracked by Wall St. Rank held Oncternal Therapeutics, Inc. Common Stock as of Q3 2022.

Based on Legal & General Group's 13F filing for Q3 2022, filed 14 Nov 2022.